|
|
Acadia Pharmaceuticals and Stoke Therapeutics Announce Collaboration to Pursue Multiple RNA-based Treatments for Severe and Rare Genetic Neurodevelopmental Diseases
|
|
|
Acadia Pharmaceuticals to Present at the 40th Annual J.P. Morgan Healthcare Conference on January 11, 2022
|
|
|
Acadia Pharmaceuticals Announces Plan for a Resubmission of its Supplemental New Drug Application to U.S. FDA for NUPLAZID® (pimavanserin)
|
|
|
Acadia Pharmaceuticals Announces Promotion of Mark Schneyer to Executive Vice President, Chief Financial Officer
|
|
|
Acadia Pharmaceuticals Announces Positive Top-line Results from the Pivotal Phase 3 Lavender Trial of Trofinetide in Rett Syndrome
|
|
|
The Lancet Psychiatry Publishes Results from ADVANCE Study Evaluating Pimavanserin Treatment for Negative Symptoms of Schizophrenia
|
|
|
Acadia Pharmaceuticals and StoryCorps Collaborate to Launch Yours, Truly – a Multicultural Storytelling Campaign to Bring Greater Awareness to Parkinson’s Disease Non-Motor Symptoms
|
|
|
Acadia Pharmaceuticals Reports Third Quarter 2021 Financial Results
|
|
|
Acadia Pharmaceuticals Presents New Dementia-Related Psychosis Real-World Outcomes Data at Psych Congress 2021
|
|
|
Acadia Pharmaceuticals Appoints Brendan Teehan, Executive Vice President, Chief Operating Officer, Head of Commercial
|
|
|
Acadia Pharmaceuticals to Announce Third Quarter 2021 Financial Results on November 8, 2021
|
|
|
Acadia Pharmaceuticals to Present Data on Pimavanserin in Patients with Parkinson’s Disease Dementia with Psychosis from the HARMONY trial at the 14th Clinical Trials on Alzheimer’s Disease (CTAD) Conference
|
|
|
Acadia Pharmaceuticals to Present at Upcoming Investor Conferences
|
|
|
Acadia Pharmaceuticals Announces Executive Leadership Change
|
|
|
Acadia Pharmaceuticals to Present at the Canaccord Genuity 41st Annual Growth Conference on August 12, 2021
|
|
|
Acadia Pharmaceuticals Reports Second Quarter 2021 Financial Results
|
|
|
The New England Journal of Medicine Publishes Results from the Phase 3 HARMONY Study Evaluating Pimavanserin in Patients with Dementia-Related Psychosis
|
|
|
Acadia Pharmaceuticals to Announce Second Quarter 2021 Financial Results on August 4, 2021
|
|
|
Acadia Pharmaceuticals to Present New Scientific Data on Pimavanserin in Neurodegenerative Diseases at the Alzheimer’s Association International Conference 2021 (AAIC)
|
|
|
NUPLAZID® (pimavanserin) Efficacy Data from Open-Label Extension (OLE) Study Published in Parkinsonism and Related Disorders
|
|
|
Acadia Pharmaceuticals to Present at Upcoming Investor Conferences
|
|
|
Acadia Pharmaceuticals Reports First Quarter 2021 Financial Results
|
|
|
Acadia Pharmaceuticals to Present at Upcoming Investor Conferences
|
|
|
Acadia Pharmaceuticals to Announce First Quarter 2021 Financial Results on May 5, 2021
|
|
|
Acadia Pharmaceuticals Receives Complete Response Letter from U.S. FDA for Supplemental New Drug Application for Pimavanserin for the Treatment of Hallucinations and Delusions Associated with Dementia-Related Psychosis
|
|
|
Acadia Pharmaceuticals Provides Regulatory Update on Supplemental New Drug Application for Pimavanserin for the Treatment of Hallucinations and Delusions Associated with Dementia-Related Psychosis
|
|
|
Acadia Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Financial Results
|
|
|
Acadia Pharmaceuticals Recognizes National Caregiver’s Day with Launch of MoreThanMemoryLoss.com
|
|
|
Acadia Pharmaceuticals to Present at Upcoming Investor Conferences
|
|
|
Acadia Pharmaceuticals to Announce Fourth Quarter and Full Year 2020 Financial Results on February 24, 2021
|
|
|
Acadia Pharmaceuticals Announces Commercial Leadership Change
|
|
|
Acadia Pharmaceuticals to Present at the 39th Annual J.P. Morgan Healthcare Conference on January 12, 2021
|
|
|
Acadia Pharmaceuticals to Present at the Stifel 2020 Virtual Healthcare Conference on November 17, 2020
|
|
|
Acadia Pharmaceuticals Reports Third Quarter 2020 Financial Results
|
|
|
Acadia Pharmaceuticals to Present New Scientific Data on Pimavanserin in Neurodegenerative Diseases at the 13th Clinical Trials on Alzheimer's Disease (CTAD) Conference
|
|
|
Acadia Pharmaceuticals to Announce Third Quarter 2020 Financial Results on November 4, 2020
|
|
|
The Lewy Body Dementia Association and Acadia Pharmaceuticals to Release Educational Version of the Highly Acclaimed Robin Williams Documentary, “Robin’s Wish”
|
|
|
Michael J. Fox Foundation and Acadia Pharmaceuticals Partner to Share Resources and Foster Dialogue on Cognitive Changes and Other Non-Motor Symptoms in Parkinson’s Disease
|
|
|
Acadia Pharmaceuticals Appoints Elizabeth Garofalo, M.D. to Board of Directors
|
|
|
ACADIA Pharmaceuticals to Present at Upcoming Investor Conferences
|
|
|
ACADIA Pharmaceuticals Appoints Gudarz Davar, M.D., as Executive Vice President and Head of Research and Development
|
|
|
ACADIA Pharmaceuticals Acquires CerSci Therapeutics, Adds Novel Pain Program to Portfolio
|
|
|
ACADIA Pharmaceuticals to Present at The JMP Securities CNS Forum on August 19, 2020
|
|
|
ACADIA Pharmaceuticals Reports Second Quarter 2020 Financial Results
|
|
|
People with Dementia and Caregivers Share the Significant Burden of Visual Hallucinations and Paranoid Delusions, New Survey Highlights
|
|
|
ACADIA Pharmaceuticals to Announce Second Quarter 2020 Financial Results on August 5, 2020
|
|
|
ACADIA Pharmaceuticals Announces U.S. FDA Accepted for Filing the Supplemental New Drug Application for NUPLAZID® (pimavanserin) for the Treatment of Hallucinations and Delusions Associated with Dementia-Related Psychosis
|
|
|
ACADIA Pharmaceuticals Announces Top-line Results from the Phase 3 CLARITY Study Evaluating Pimavanserin for the Adjunctive Treatment of Major Depressive Disorder
|
|
|
ACADIA Pharmaceuticals Submits Supplemental New Drug Application to U.S. FDA for NUPLAZID® (pimavanserin) for the Treatment of Hallucinations and Delusions Associated with Dementia-Related Psychosis
|
|
|
ACADIA Pharmaceuticals to Present at the Goldman Sachs 41st Annual Global Healthcare Conference on June 9, 2020
|
|
|
ACADIA Pharmaceuticals Appoints Mark Schneyer as Senior Vice President, Business Development and Chief Business Officer
|
|
|
ACADIA Pharmaceuticals to Combine CLARITY-2 and CLARITY-3 Phase 3 Studies Evaluating Pimavanserin for the Adjunctive Treatment of Major Depressive Disorder
|
|
|
ACADIA Pharmaceuticals to Present Pimavanserin Clinical Data at the 2020 American Society of Clinical Psychopharmacology Virtual Annual Meeting
|
|
|
ACADIA Pharmaceuticals Reports First Quarter 2020 Financial Results
|
|
|
ACADIA Pharmaceuticals and Vanderbilt University Announce Exclusive License Agreement and Research Collaboration
|
|
|
ACADIA Pharmaceuticals to Present at Two Upcoming Virtual Investor Conferences
|
|
|
ACADIA Pharmaceuticals to Announce First Quarter 2020 Financial Results on May 7, 2020
|
|
|
ACADIA Pharmaceuticals and Neuren Pharmaceuticals Announce Rare Pediatric Disease Designation for Trofinetide for the Treatment of Rett Syndrome
|
|
|
ACADIA Pharmaceuticals Reports Fourth Quarter and Full Year 2019 Financial Results
|
|
|
ACADIA Pharmaceuticals to Present at the Cowen and Company 40th Annual Health Care Conference on March 2, 2020
|
|
|
ACADIA Pharmaceuticals to Announce Fourth Quarter and Full Year 2019 Financial Results on February 26, 2020
|
|
|
ACADIA Pharmaceuticals to Present at the 38th Annual J.P. Morgan Healthcare Conference on January 14, 2020
|
|
|
ACADIA Pharmaceuticals Appoints Stephanie Fagan as Senior Vice President, Corporate Affairs and Chief Communications Officer
|
|
|
ACADIA Pharmaceuticals Presents Positive Top-line Results from Pivotal Phase 3 HARMONY Trial of Pimavanserin in Patients with Dementia-Related Psychosis at 12th Clinical Trials on Alzheimer’s Disease (CTAD) Meeting
|
|
|
ACADIA Pharmaceuticals Announces Positive Top-line Results from ADVANCE Trial of Pimavanserin as Treatment for Negative Symptoms of Schizophrenia
|
|
|
ACADIA Pharmaceuticals to Host Investor Event and Webcast From Clinical Trials on Alzheimer’s Disease (CTAD) Meeting on December 4, 2019
|
|
|
ACADIA Pharmaceuticals Appoints Ponni Subbiah, M.D., M.P.H., as Senior Vice President, Global Head of Medical Affairs and Chief Medical Officer
|
|
|
ACADIA Pharmaceuticals Initiates Phase 3 Pivotal Study of Trofinetide in Rett Syndrome, a Rare Neurodevelopmental Congenital CNS Disorder
|
|
|
ACADIA Pharmaceuticals Reports Third Quarter 2019 Financial Results
|
|
|
ACADIA Pharmaceuticals to Announce Third Quarter 2019 Financial Results on October 30, 2019
|
|
|
ACADIA Pharmaceuticals Presents Additional Positive Data from the Phase 2 CLARITY Study with Pimavanserin in Adjunctive Major Depressive Disorder at 2019 Psych Congress
|
|
|
ACADIA Pharmaceuticals Announces Late-Breaking Oral Presentation of the Phase 3 HARMONY Study of Pimavanserin in Dementia-Related Psychosis at the Clinical Trials on Alzheimer’s Disease (CTAD) 2019 Meeting
|
|
|
ACADIA Pharmaceuticals to Present at the 2019 Cantor Global Healthcare Conference on October 2, 2019
|
|
|
ACADIA Pharmaceuticals Announces that The Journal of Clinical Psychiatry Publishes Positive Phase 2 CLARITY Results for Pimavanserin as Adjunctive Treatment for Patients with Major Depressive Disorder
|
|
|
ACADIA Pharmaceuticals Presents New Data on PD Patients Treated with Pimavanserin for Depression at the 2019 International Congress of Parkinson’s Disease and Movement Disorders
|
|
|
ACADIA Pharmaceuticals Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares
|
|
|
ACADIA Pharmaceuticals to Present New Clinical Data and Outcomes Research at Upcoming Scientific Meetings
|
|
|
ACADIA Pharmaceuticals Prices Public Offering of Common Stock
|
|
|
ACADIA Pharmaceuticals Announces Proposed Public Offering of Common Stock
|
|
|
ACADIA Pharmaceuticals Announces Pivotal Phase 3 HARMONY Trial Stopped Early for Positive Efficacy as Pimavanserin Meets the Primary Endpoint in Patients with Dementia-Related Psychosis
|
|
|
ACADIA Pharmaceuticals to Present at the Morgan Stanley 17th Annual Global Healthcare Conference on September 11, 2019
|
|
|
ACADIA Pharmaceuticals Reports Second Quarter 2019 Financial Results
|
|
|
ACADIA Pharmaceuticals Announces Top-line Results from Phase 3 ENHANCE Trial of Pimavanserin as Adjunctive Treatment for Patients with Schizophrenia
|
|
|
ACADIA Pharmaceuticals to Announce Second Quarter 2019 Financial Results on July 31, 2019
|
|
|
New National Event Series "Parkinson's IQ + You" Launches to Educate and Empower Parkinson's Disease Patients and Care Partners
|
|
|
ACADIA Pharmaceuticals to Present at the Goldman Sachs 40th Annual Global Healthcare Conference
|
|
|
ACADIA Pharmaceuticals to Present Phase 2 CLARITY Results for Pimavanserin as an Adjunctive Treatment in Major Depressive Disorder at the 2019 American Psychiatric Association Annual Meeting
|
|
|
ACADIA Pharmaceuticals to Present at the Bank of America Merrill Lynch Health Care Conference 2019
|
|
|
ACADIA Pharmaceuticals Reports First Quarter 2019 Financial Results
|
|
|
ACADIA Pharmaceuticals Initiates Phase 3 CLARITY Program with Pimavanserin as Adjunctive Treatment for Major Depressive Disorder
|
|
|
ACADIA Pharmaceuticals to Announce First Quarter 2019 Financial Results on May 1, 2019
|
|
|
ACADIA Pharmaceuticals Supports Parkinson’s Disease Awareness Month and World Parkinson’s Day with Local Educational Initiatives and Community Events Across the Country
|
|
|
ACADIA Pharmaceuticals to Present at the 18th Annual Needham Healthcare Conference on April 9, 2019
|
|
|
ACADIA Pharmaceuticals Announces Promotion of Elena Ridloff, CFA to Executive Vice President, Chief Financial Officer
|
|
|
Positive Phase 2 Study Results of Trofinetide in Pediatric Rett Syndrome Published in Neurology, the Medical Journal of the American Academy of Neurology
|
|
|
ACADIA Pharmaceuticals to Present at the Cowen and Company 39th Annual Health Care Conference on March 11, 2019
|
|
|
ACADIA Pharmaceuticals Reports Fourth Quarter and Full Year 2018 Financial Results
|
|
|
ACADIA Pharmaceuticals to Present at the 8th Annual Leerink Partners Global Healthcare Conference on February 28, 2019
|
|
|
ACADIA Pharmaceuticals to Announce Fourth Quarter and Full Year 2018 Financial Results on February 26, 2019
|
|
|
ACADIA Pharmaceuticals to Present at the 37th Annual J.P. Morgan Healthcare Conference on January 9, 2019
|
|
|
ACADIA Pharmaceuticals Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares
|
|
|
ACADIA Pharmaceuticals Prices Public Offering of Common Stock
|
|
|
ACADIA Pharmaceuticals Announces Proposed Public Offering of Common Stock
|
|
|
ACADIA Pharmaceuticals Reports Third Quarter 2018 Financial Results
|
|
|
ACADIA Pharmaceuticals Announces Positive Top-line Results from Phase 2 CLARITY Trial of Pimavanserin for Adjunctive Treatment in Patients with Major Depressive Disorder (MDD)
|
|
|
ACADIA Pharmaceuticals Announces Executive Leadership Change
|
|
|
ACADIA Pharmaceuticals to Announce Third Quarter 2018 Financial Results on November 6, 2018
|
|
|
ACADIA Pharmaceuticals Announces Executive Appointments to Lead Medical Affairs and Science
|
|
|
ACADIA Pharmaceuticals to Present at the 2018 Cantor Global Healthcare Conference on October 2, 2018
|
|
|
FDA Issues Statement Reaffirming the Positive Benefit-Risk Profile of NUPLAZID® (pimavanserin) for Patients with Hallucinations and Delusions Associated with Parkinson’s Disease Psychosis
|
|
|
Analyses of Pimavanserin Studies Evaluating Treatment in Alzheimer’s Disease Psychosis and Parkinson’s Disease Psychosis Published in The Journal of Prevention of Alzheimer’s Disease Suggest Potential for Treating Dementia-Related Psychosis
|
|
|
ACADIA Pharmaceuticals to Present at the Morgan Stanley 16th Annual Global Healthcare Conference on September 13, 2018
|
|
|
ACADIA Pharmaceuticals Reports Second Quarter 2018 Financial Results
|
|
|
ACADIA Pharmaceuticals and Neuren Pharmaceuticals Announce Exclusive License Agreement for the North American Development and Commercialization of Trofinetide in Rett Syndrome
|
|
|
ACADIA Pharmaceuticals to Announce Second Quarter 2018 Financial Results on August 8, 2018
|
|
|
ACADIA Pharmaceuticals Announces Appointment of Austin D. Kim as Executive Vice President, General Counsel and Secretary
|
|
|
ACADIA Pharmaceuticals Announces FDA Approval of New Dosing Formulation and Strength for NUPLAZID® (Pimavanserin)
|
|
|
ACADIA Pharmaceuticals to Present at the JMP Securities Life Sciences Conference on June 20, 2018
|
|
|
ACADIA Pharmaceuticals to Present at the Goldman Sachs 39th Annual Global Healthcare Conference on June 13, 2018
|
|
|
ACADIA Pharmaceuticals to Present at the Bank of America Merrill Lynch Health Care Conference 2018
|
|
|
ACADIA Pharmaceuticals Reports First Quarter 2018 Financial Results
|
|
|
ACADIA Pharmaceuticals Announces Appointment of Elena Ridloff, CFA, as Senior Vice President, Investor Relations
|
|
|
ACADIA Pharmaceuticals to Announce First Quarter 2018 Financial Results on May 4, 2018
|
|
|
ACADIA Pharmaceuticals Issues Statement Reaffirming Benefit/Risk Profile of NUPLAZID
|
|
|
ACADIA Pharmaceuticals Announces Presentation of Clinical Experience Data for NUPLAZID (Pimavanserin) at 2018 American Academy of Neurology (AAN) Annual Meeting
|
|
|
PMDAlliance and ACADIA Pharmaceuticals Survey Reveals Serious Quality-of-Life Impact of Non-Movement Symptoms of Parkinson’s Disease
|
|
|
ACADIA Pharmaceuticals to Present at the 17th Annual Needham Healthcare Conference on March 27, 2018
|
|
|
ACADIA Pharmaceuticals to Present at the Cowen and Company 38th Annual Health Care Conference on March 13, 2018
|
|
|
ACADIA Pharmaceuticals Reports Fourth Quarter and Full Year 2017 Financial Results
|
|
|
ACADIA Pharmaceuticals to Announce Fourth Quarter and Full Year 2017 Financial Results on February 27, 2018
|
|
|
ACADIA Pharmaceuticals to Present at the 36th Annual J.P. Morgan Healthcare Conference on January 9, 2018
|
|
|
ACADIA Pharmaceuticals Announces Appointment of Damien McDevitt, Ph.D., as Senior Vice President, Corporate Development
|
|
|
ACADIA Pharmaceuticals to Present at the 29th Annual Piper Jaffray Healthcare Conference on November 28, 2017
|
|
|
ACADIA Pharmaceuticals Reports Third Quarter 2017 Financial Results
|
|
|
ACADIA Pharmaceuticals Presents Data from the Phase II Study of Pimavanserin in Alzheimer’s Disease Psychosis at the Clinical Trials on Alzheimer’s Disease (CTAD) 2017 Meeting
|
|
|
ACADIA Pharmaceuticals to Announce Third Quarter 2017 Financial Results on November 7, 2017
|
|
|
ACADIA Pharmaceuticals Initiates Phase III Study of Pimavanserin in Dementia-Related Psychosis
|
|
|
ACADIA Pharmaceuticals to Present at the Ladenburg Thalmann 2017 Healthcare Conference on September 26, 2017
|
|
|
ACADIA Pharmaceuticals Reports Second Quarter 2017 Financial Results
|
|
|
ACADIA Pharmaceuticals to Announce Second Quarter 2017 Financial Results on August 8, 2017
|
|
|
ACADIA Pharmaceuticals Named to Forbes Magazine’s List of World’s Most Innovative Growth Companies
|
|
|
ACADIA Pharmaceuticals Reports First Quarter 2017 Financial Results
|
|
|
ACADIA Pharmaceuticals to Present at the Bank of America Merrill Lynch 2017 Healthcare Conference on May 16, 2017
|
|
|
ACADIA Pharmaceuticals to Announce First Quarter 2017 Financial Results on May 9, 2017
|
|
|
ACADIA Pharmaceuticals Announces Appointment of Michael J. Yang as Executive Vice President, Chief Commercial Officer
|
|
|
ACADIA Pharmaceuticals to Present at Needham & Company’s 16th Annual Healthcare Conference on April 5, 2017
|
|
|
ACADIA Pharmaceuticals Reports Financial Results for the Fourth Quarter and Year Ended December 31, 2016
|
|
|
ACADIA Pharmaceuticals to Present at the Cowen and Company 37th Annual Health Care Conference on March 6, 2017
|
|
|
ACADIA Pharmaceuticals to Announce Fourth Quarter and Full Year 2016 Financial Results on February 28, 2017
|
|
|
ACADIA Pharmaceuticals to Present at the 35th Annual J.P. Morgan Healthcare Conference on January 10, 2017
|
|
|
ACADIA Pharmaceuticals Announces Positive Top-Line Results From Phase II Study of Pimavanserin for Alzheimer’s Disease Psychosis
|
|
|
ACADIA Pharmaceuticals Initiates Phase II Trial of Pimavanserin for Adjunctive Treatment in Patients With Major Depressive Disorder
|
|
|
ACADIA Pharmaceuticals Initiates Phase II Trial of Pimavanserin for Adjunctive Treatment in Patients With Negative Symptoms of Schizophrenia
|
|
|
ACADIA Pharmaceuticals Reports Third Quarter 2016 Financial Results
|
|
|
ACADIA Pharmaceuticals Initiates Phase III Trial of Pimavanserin for Adjunctive Treatment in Patients with Schizophrenia
|
|
|
ACADIA Pharmaceuticals to Announce Third Quarter 2016 Financial Results on November 7, 2016
|
|
|
ACADIA Pharmaceuticals Initiates Phase II Study of Pimavanserin in Alzheimer’s Disease Agitation
|
|
|
ACADIA Pharmaceuticals Receives California Life Sciences Association’s 2016 Pantheon DiNA Award for Outstanding Therapeutic Product for NUPLAZID™
|
|
|
ACADIA Pharmaceuticals to Present at the Ladenburg Thalmann 2016 Healthcare Conference on September 27, 2016
|
|
|
ACADIA Pharmaceuticals Sponsors National Parkinson Foundation’s Caregiver Summit
|
|
|
ACADIA Pharmaceuticals to Present at the Morgan Stanley Global Healthcare Conference on September 12, 2016
|
|
|
ACADIA Pharmaceuticals Announces Appointment of Todd S. Young as Executive Vice President, Chief Financial Officer
|
|
|
ACADIA Pharmaceuticals Announces Full Exercise of Underwriters’ Option to Purchase Additional Shares
|
|
|
ACADIA Pharmaceuticals Prices Public Offering of Common Stock
|
|
|
ACADIA Pharmaceuticals Announces Proposed Public Offering of Common Stock
|
|
|
ACADIA Pharmaceuticals Reports Second Quarter 2016 Financial Results
|
|
|
ACADIA Pharmaceuticals to Announce Second Quarter 2016 Financial Results on August 4, 2016
|
|
|
ACADIA Pharmaceuticals Added to Large-Cap Russell 1000 Market Index
|
|
|
ACADIA Pharmaceuticals to Present at the JMP Securities Life Sciences Conference on June 21, 2016
|
|
|
ACADIA Pharmaceuticals to Present at the Goldman Sachs 37th Annual Global Healthcare Conference on June 8, 2016
|
|
|
ACADIA Pharmaceuticals Announces NUPLAZID™ (pimavanserin) Is Now Available for the Treatment of Hallucinations and Delusions Associated with Parkinson’s Disease Psychosis
|
|
|
ACADIA Pharmaceuticals Reports First Quarter 2016 Financial Results
|
|
|
ACADIA Pharmaceuticals to Present at the Bank of America Merrill Lynch 2016 Health Care Conference on May 11, 2016
|
|
|
ACADIA Pharmaceuticals to Announce First Quarter 2016 Financial Results on May 5, 2016
|
|
|
FDA Approves ACADIA Pharmaceuticals’ NUPLAZID™ (pimavanserin) - The First Drug Approved for the Treatment of Hallucinations and Delusions Associated with Parkinson’s Disease Psychosis
|
|
|
ACADIA Pharmaceuticals to Present at the 15th Annual Needham Healthcare Conference on April 12, 2016
|
|
|
FDA Advisory Committee Votes 12 to 2 That Benefits of ACADIA Pharmaceuticals’ NUPLAZID™ (Pimavanserin) for the Treatment of Psychosis Associated with Parkinson’s Disease Outweigh the Risks
|
|
|
ACADIA Pharmaceuticals Stock Trading Halted Today
|
|
|
ACADIA Pharmaceuticals to Present at the Cowen and Company 36th Annual Health Care Conference on March 8, 2016
|
|
|
ACADIA Pharmaceuticals Reports Financial Results for the Fourth Quarter and Year Ended December 31, 2015
|
|
|
ACADIA Pharmaceuticals to Announce Fourth Quarter and Full Year 2015 Financial Results on February 29, 2016
|
|
|
ACADIA Pharmaceuticals to Present at the LEERINK Partners 5th Annual Global Healthcare Conference on February 10, 2016
|
|
|
ACADIA Pharmaceuticals Announces FDA Advisory Committee Meeting to Review NUPLAZID™ (Pimavanserin) for the Treatment of Parkinson’s Disease Psychosis
|
|
|
ACADIA Pharmaceuticals Appoints James (Randy) R. Owen, M.D., as Senior Vice President, Clinical Development and Chief Medical Officer
|
|
|
ACADIA Pharmaceuticals Appoints Jim Daly to Board of Directors
|
|
|
ACADIA Pharmaceuticals to Present at the 34th Annual J.P. Morgan Healthcare Conference on January 12, 2016
|
|
|
ACADIA Pharmaceuticals Prices Public Offering of Common Stock
|
|
|
ACADIA Pharmaceuticals Announces Proposed Public Offering of Common Stock
|
|
|
ACADIA Pharmaceuticals Appoints Julian C. Baker to Board of Directors
|
|
|
ACADIA Pharmaceuticals Appoints Srdjan (Serge) Stankovic, M.D., M.S.P.H., as Executive Vice President, Head of Research and Development
|
|
|
ACADIA Pharmaceuticals Appoints Edmund P. Harrigan, M.D., to Board of Directors
|
|
|
ACADIA Pharmaceuticals Reports Third Quarter 2015 Financial Results
|
|
|
ACADIA Pharmaceuticals to Present at the 24th Annual Credit Suisse Healthcare Conference on November 10, 2015
|
|
|
ACADIA Pharmaceuticals Announces FDA Priority Review of NUPLAZID™ (Pimavanserin) New Drug Application for Parkinson’s Disease Psychosis
|
|
|
ACADIA Pharmaceuticals to Announce Third Quarter Financial Results on November 5, 2015
|
|
|
ACADIA Pharmaceuticals to Present at the Ladenburg Thalmann 2015 Healthcare Conference on September 29, 2015
|
|
|
ACADIA Pharmaceuticals Appoints Steve Davis as Chief Executive Officer
|
|
|
ACADIA Pharmaceuticals Submits New Drug Application for NUPLAZID™ for the Treatment of Parkinson’s Disease Psychosis
|
|
|
ACADIA Pharmaceuticals Reports Second Quarter 2015 Financial Results
|
|
|
ACADIA Pharmaceuticals Announces Publication of Data from Its -015 Open Label Safety Study in Parkinson’s Disease Psychosis in the Journal of the American Medical Directors Association
|
|
|
ACADIA Pharmaceuticals Announces Senior Management Appointments in Manufacturing, Quality, Compliance, Access and Reimbursement and Business Development
|
|
|
ACADIA Pharmaceuticals to Announce Second Quarter Financial Results on August 6, 2015
|
|
|
ACADIA Pharmaceuticals to Present at the JMP Securities Life Sciences Conference on June 24, 2015
|
|
|
ACADIA Pharmaceuticals Presents Integrated Data from Its Phase III Program with NUPLAZID™ (Pimavanserin) for Parkinson’s Disease Psychosis at the 19th International Congress of Parkinson’s Disease and Movement Disorders
|
|
|
ACADIA Pharmaceuticals to Present at the Jefferies 2015 Healthcare Conference on June 2, 2015
|
|
|
ACADIA Pharmaceuticals Reports First Quarter 2015 Financial Results
|
|
|
ACADIA Pharmaceuticals to Present at the Bank of America Merrill Lynch 2015 Health Care Conference on May 13, 2015
|
|
|
ACADIA Pharmaceuticals to Announce First Quarter Financial Results on May 7, 2015
|
|
|
ACADIA Pharmaceuticals to Present at the 14th Annual Needham Healthcare Conference on April 14, 2015
|
|
|
ACADIA Pharmaceuticals Appoints Daniel Soland to Board of Directors
|
|
|
ACADIA Pharmaceuticals Announces Retirement of Uli Hacksell, Ph.D., Chief Executive Officer
|
|
|
ACADIA Pharmaceuticals Updates Planned Timing of NUPLAZID™ NDA Submission
|
|
|
ACADIA Pharmaceuticals Reports Financial Results for the Fourth Quarter and Year Ended December 31, 2014
|
|
|
ACADIA Pharmaceuticals to Present at Upcoming Investor Conferences
|
|
|
ACADIA Pharmaceuticals to Announce Fourth Quarter and Full Year 2014 Financial Results on February 26, 2015
|
|
|
ACADIA Pharmaceuticals to Present at the 33rd Annual J.P. Morgan Healthcare Conference on January 13, 2015
|
|
|
ACADIA Pharmaceuticals Presents Caregiver Burden Data at the International Congress of Non-Motor Dysfunctions in Parkinson’s Disease and Related Disorders
|
|
|
ACADIA Pharmaceuticals to Present at Upcoming Investor Conferences
|
|
|
ACADIA Pharmaceuticals to Present at Jefferies 2014 Global Healthcare Conference on November 20, 2014
|
|
|
ACADIA Pharmaceuticals Reports Third Quarter 2014 Financial Results and Updates Timing of NUPLAZID™ NDA Submission
|
|
|
ACADIA Pharmaceuticals to Announce Third Quarter 2014 Financial Results on November 10, 2014
|
|
|
ACADIA Pharmaceuticals Receives FDA Breakthrough Therapy Designation for NUPLAZID™ (Pimavanserin) for Parkinson’s Disease Psychosis
|
|
|
ACADIA Pharmaceuticals Announces Trade Name NUPLAZID™ for Pimavanserin
|
|
|
ACADIA Pharmaceuticals Reports Second Quarter 2014 Financial Results
|
|
|
ACADIA Pharmaceuticals to Announce Second Quarter 2014 Financial Results on August 5, 2014
|
|
|
ACADIA Pharmaceuticals Announces Appointment of Stephen Davis as Executive Vice President, Chief Financial Officer and Chief Business Officer
|
|
|
ACADIA Pharmaceuticals to Present at the 9th Annual JMP Securities Healthcare Conference on June 24, 2014
|
|
|
ACADIA Pharmaceuticals to Present at the Jefferies 2014 Global Healthcare Conference on June 2, 2014
|
|
|
ACADIA Pharmaceuticals Reports First Quarter 2014 Financial Results
|
|
|
ACADIA Pharmaceuticals to Present at Upcoming Investor Conferences
|
|
|
ACADIA Pharmaceuticals to Announce First Quarter 2014 Financial Results on May 6, 2014
|
|
|
ACADIA Pharmaceuticals to Present at the 13th Annual Needham Healthcare Conference on April 8, 2014
|
|
|
ACADIA Pharmaceuticals to Present at Upcoming Investor Conferences
|
|
|
ACADIA Pharmaceuticals Prices Public Offering of Common Stock
|
|
|
ACADIA Pharmaceuticals Announces Proposed Public Offering of Common Stock
|
|
|
ACADIA Pharmaceuticals Reports Financial Results for the Fourth Quarter and Year Ended December 31, 2013
|
|
|
ACADIA Pharmaceuticals to Announce Fourth Quarter and Full Year 2013 Financial Results on February 27, 2014
|
|
|
ACADIA Pharmaceuticals to Present at Upcoming Investor Conferences
|
|
|
ACADIA Pharmaceuticals Announces Initiation of Phase II Trial with Pimavanserin for Alzheimer’s Disease Psychosis
|
|
|
ACADIA Pharmaceuticals Reports Third Quarter 2013 Financial Results
|
|
|
ACADIA Pharmaceuticals Announces Publication in The Lancet of Pivotal Phase III Parkinson’s Disease Psychosis Trial with Pimavanserin
|
|
|
ACADIA Pharmaceuticals to Announce Third Quarter 2013 Financial Results on November 6, 2013
|
|
|
ACADIA Pharmaceuticals to Present at Upcoming Investor Conferences
|
|
|
ACADIA Pharmaceuticals Announces Appointment of Terrence Moore as Executive Vice President and Chief Commercial Officer
|
|
|
ACADIA Pharmaceuticals Reports Second Quarter 2013 Financial Results
|
|
|
ACADIA Pharmaceuticals to Announce Second Quarter 2013 Financial Results on August 6, 2013
|
|
|
ACADIA Pharmaceuticals to Present at the 8th Annual JMP Securities Healthcare Conference on July 9, 2013
|
|
|
ACADIA Pharmaceuticals Added to Russell 2000 Index
|
|
|
ACADIA Pharmaceuticals Announces Multiple Presentations of Data from Phase III Pimavanserin Program at the 17th International Congress of Parkinson’s Disease and Movement Disorders
|
|
|
ACADIA Pharmaceuticals Announces Advancement by Allergan of Novel Glaucoma Compound into Preclinical Development
|
|
|
ACADIA Pharmaceuticals to Present at the Jefferies Global Healthcare Conference on June 5, 2013
|
|
|
ACADIA Pharmaceuticals Announces Exercise in Full of Option to Purchase Additional Shares and Completion of Public Offering of Common Stock
|
|
|
ACADIA Pharmaceuticals Added to NASDAQ Biotechnology Index
|
|
|
ACADIA Pharmaceuticals Prices Public Offering of Common Stock
|
|
|
ACADIA Pharmaceuticals Announces Proposed Public Offering of Common Stock
|
|
|
ACADIA Pharmaceuticals Reports First Quarter 2013 Financial Results
|
|
|
ACADIA Pharmaceuticals to Announce First Quarter 2013 Financial Results on May 7, 2013
|
|
|
ACADIA Pharmaceuticals to Present at the 12th Annual Needham Healthcare Conference on April 30, 2013
|
|
|
ACADIA Pharmaceuticals Announces Expedited Path to NDA Filing for Pimavanserin Following Meeting with FDA
|
|
|
ACADIA Announces Presentation of Data from Its Pivotal Phase III Parkinson’s Disease Psychosis Study with Pimavanserin at the American Academy of Neurology Annual Meeting
|
|
|
ACADIA Pharmaceuticals to Present at the 25th Annual ROTH Conference on March 19, 2013
|
|
|
ACADIA Pharmaceuticals Reports Financial Results for the Fourth Quarter and Year Ended December 31, 2012
|
|
|
ACADIA Pharmaceuticals to Announce Fourth Quarter and Full Year 2012 Financial Results on March 12, 2013
|
|
|
ACADIA Pharmaceuticals to Present at the Cowen and Company 33rd Annual Health Care Conference on March 4, 2013
|
|
|
ACADIA Pharmaceuticals to Present at the 15th Annual BIO CEO & Investor Conference on February 12, 2013
|
|
|
ACADIA Pharmaceuticals Announces Election of Stephen R. Biggar to Its Board of Directors
|
